

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-54. (Canceled)

55. (Currently amended) A method of treating macular degeneration, which comprises administering to a patient in need thereof a therapeutically effective amount of a ~~selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein said selective cytokine inhibitory drug is (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonyl ethyl]-4-acetylaminoisindoline-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof~~ 3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isindol-2-yl)-propionamide, or cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isindol-4-yl}-amide.

56-57. (Canceled)

58. (Currently amended) The method of ~~one of claims 23-57~~ claim 55, which further comprises administering to the patient a therapeutically effective amount of at least one second active agent.

59. (Previously presented) The method of claim 58, wherein the second active agent is a steroid, a light sensitizer, an integrin, an antioxidant, an interferon, a xanthine derivative, a growth hormone, a neutrotrophic factor, a regulator of neovascularization, an anti-VEGF antibody, a prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound or an antiangiogenesis compound.

60. (Previously presented) The method of claim 58, wherein the second active agent is thalidomide, verteporfin, purlytin, an angiostatic steroid, rhuFab, interferon-2 α or pentoxifylline, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

61. (Previously presented) The method of claim 59, wherein antiangiogenesis compound is thalidomide.

62. (Currently amended) The method of ~~one of claims 23-57~~ claim 55, wherein the macular degeneration is wet macular degeneration, dry macular degeneration, age-related macular degeneration, age-related maculopathy, choroidal neovascularisation, retinal pigment epithelium detachment, atrophy of retinal pigment epithelium, Best's disease, vitelliform, Stargardt's disease, juvenile macular dystrophy, fundus flavimaculatus, Behr's disease, Sorsby's disease, Doyne's disease, honeycomb dystrophy, or macular damaging condition.

63. (Currently amended) The method of ~~one of claims 23-57~~ claim 55, wherein the ~~stereoisomer of the selective cytokine inhibitory drug~~ compound is enantiomerically pure.

64. (Currently amended) The method of ~~one of claims 23-57~~ claim 55, wherein the ~~selective cytokine inhibitory drug~~ compound can be administered before, during or after surgical intervention directed at reducing or avoiding a symptom of macular degeneration in the patient.

65. (Previously presented) The method of claim 64, wherein the surgical intervention is light therapy, laser therapy, radiation therapy, retinal pigment epithelium transplantation, or foveal translocation.

66. (Currently amended) The method of ~~one of claims 23-57~~ claim 55, wherein the ~~selective cytokine inhibitory drug~~ compound is administered orally or topically.

67. (Currently amended) The method of claim 66, wherein the ~~selective cytokine inhibitory drug~~ compound is administered in the form of a solution, capsule or tablet.